- Advisory Board
- Who attends?
- Sponsors and Partners
- All Years
- The Dorchester, London
Over 200 senior pharma executives gathered at The Dorchester on February 10th to discuss how the pharma industry needs to rebuild its image and position itself as a key industry in tomorrow’s marketplace.
Today’s big pharma companies would have been almost unrecognisable ten years ago. No longer able to rely on patented drugs for their revenue streams, pharma companies have been diversifying into new products – from generics to animal health and consumer healthcare - and into new markets, especially the fast-growing Asian economies.
But is this trajectory sustainable in the long-term? And will R&D-led pharma ever be able to generate the profits of former decades?
Join the debate where top pharma players will share their thoughts on the out look for the pharma industry in the long term and discuss the business models for future success.
|GAIN INSIGHTS FROM THE INDUSTRY'S LEADING CHIEF EXECUTIVES: hear their unique visions for the future of pharma|
|LEARN WHICH BUSINESS PORTFOLIOS will give your company the competitive advantage in the new high growth economies|
|DISCOVER HOW PHARMA CAN RE-ESTABLISH TRUST and how to adapt the pharma business model to capture value in new ways
|GATHER TIPS on how to make personalised medicine pay its way|
|HEAR THE ECONOMIST INTELLIGENCE UNIT'S LATEST FORECAST: for the markets that will lead the industry's growth in 2011|
|MEET OVER 150 SENIOR EXECUTIVES from across pharma and network with leading influential thinkers in the industry|
|08.15 ||REGISTRATION AND REFRESHMENTS|
CHAIR'S OPENING REMARKS
Iain Scott, Managing Editor, Business Research, Economist Intelligence Unit
THE NEW PHARMA: MODELS FOR FUTURE GROWTH
OPENING ADDRESS: Is there a future for the research-led pharma company?
John Lechleiter, Chairman, President and Chief Executive Officer, Eli Lilly
KEYNOTE ADDRESS: Pharma’s value proposition - how the industry must change
David Redfern, Chief Strategy Officer, GlaxoSmithKline
PANEL: Where’s hot and where’s not: Seeking opportunities in tomorrow’s markets
• What sort of portfolios will companies need to serve these markets? What will the business model need to be?
• Local players vs. new entrants: what are the dynamics? How can western pharma compete in the absence of a level playing field? What is the impact of the Bribery Act and similar anti-corruption legislation?
Jesper Høiland, Senior Vice-president, International Operations, Novo Nordisk
|11.15||NETWORKING REFRESHMENT BREAK|
PANEL: Forget command and control – try engagement: Repositioning pharma for a new era
• How can pharma re-establish trust with patients, investors and diverse stakeholders?
Patrick Flochel, Partner, EMEIA Life Sciences Leader, Global Life Sciences Centre, Ernst & Young
Chaired by Peter Collins, Online Business and Finance Editor, The Economist
|THE FUTURE OF MEDICINE: WHAT ROLE WILL PHARMA PLAY?|
PRESENTATION: Moving away from the blockbusters: innovative approaches to orphan diseases
Nicolas Sireau, Chairman, AKU Society
Chaired by: Tom Standage, Digital Editor, The Economist
PANEL: The case for personalised medicine – is this the future and, if so, how will we pay for it?
Chaired by: Tom Standage, Digital Editor, The Economist
|15.30||NETWORKING REFRESHMENT BREAK|
|15.45||A NEW MODEL FOR HEALTHCARE – how does Pharma fit?|
The founder of revolutionary healthcare company PatientsLikeMe will explain how he sees opportunities opening up for the pharma industry in new healthcare models.
Jamie Heywood, Co-Founder and Chairman, PatientsLikeMe
|16.10||CLOSING ADDRESS: Rebranding pharma|
Hear how pharma can change its image from a leading brand expert. What does it take to shake off the negative connotations and be seen as a “star” industry again?
Jonathan Sands, Chairman, Elmwood
|16.40||CHAIR'S CLOSING REMARKS|
|16.50||CLOSE OF CONFERENCE|
DRINKS RECEPTION: SPONSORED BY ENTERPRISE IRELAND
To be held at the Irish Embassy (transportation will be provided)
|OPENING ADDRESS: John Lechleiter, Chairman, President and Chief Executive Officer, Eli Lilly|
The CEO of one of the world’s biggest pharma companies will open the conference by sharing his views on the future of the industry, and poses the question: can big pharma can continue to be research-led?
|KEYNOTE ADDRESS: David Redfern, Chief Strategy Officer, GlaxoSmithKline|
David will give a fascinating insight not only into GSK’s strategy, but also a broader viewpoint on how the Pharma industry is responding to today’s challenges.
|Jesper Høiland, Senior Vice-president, International Operations, Novo Nordisk|
Novo Nordisk are a big player in emerging markets, and India in particular, and Jesper will share with us his views on how these markets are developing and creating new opportunities for the pharma industry.
|Ken Jones, Chief Operations Officer, Astellas Pharma Europe|
With 25 years of experience in the pharmaceutical industry across a range of regions and functions, Ken represents Astellas, a big strategic player in emerging markets, which will ensure a broad and informed viewpoint on the key issues facing the industry in this area.
|Martin Mackay, President, Research and Development, AstraZeneca|
As head of R&D for AstraZeneca, a company that is adapting its business structure to take advantage of the opportunities in targeted therapies, Martin will have valuable insights to share in the debate on personalised medicine.
|Debasish Roychowdhury, Senior Vice-president and Chief Oncology Officer, Sanofi-Aventis|
Sanofi-Aventis are one of several pharma companies that are changing their business strategies to develop drugs that target smaller populations, and in his role as head of global oncology, Dr Roychowdhury ‘s viewpoint will add great value to the discussion on personalised medicine.
Felix Frueh, President, Medco Health Institute
With a background in academia and at the FDA, Felix has a wealth of valuable experience to bring to the debate, and delegates will also benefit from his in-depth knowledge of the US healthcare landscape.
|Patrick Flochel, Partner, EMEIA Life Sciences Leader, Ernst & Young|
Patrick’s work with major global clients in the EMEIA region in the life sciences, pharma and medical devices sectors ensures that he is optimally positioned to have an overview of key trends in the industry and their implications.
|David Bott, Director of Innovation Programmes, Technology Strategy Board|
The Technology Strategy board is an organisation focused on driving and fostering innovation in the UK, and personalized medicine is one of their key target areas. As Director of Innovation, David will be able to share valuable insights into the latest developments.
|Jonathan Sands OBE, Chairman, Elmwood|
Hailing from the multi-award-winning brand consultancy Elmwood, Jonathan will offer creative ideas for how Pharma can turn around negative perceptions and renew its image.
Håkan Björklund, Chief Executive Officer, Nycomed
As leader of a growing pharma company which is now in the world’s top 25, Håkan can offer a welcome insight into which strategies will pay off for the industry to position itself in a rapidly changing healthcare landscape.
Kemal Malik, Member of the Board of Management and Head of Global Development, Bayer HealthCare
With a background in medicine as well as a management board position at Bayer, Dr Malik will have a broad perspective on how the industry should respond to the needs of different stakeholders.
Described as "inspirational and innovative" Dr Nick Sireau will share his experiences in the identification and treatment of rare diseases, and how the pharma industry can adapt its business model to take advantage of the opportunities in this area
Jeremy is the voice of National Voices, which represents 15 million patients, and we’ll hear from him how the pharma industry can best serve the needs of the patient and carer com munity.
Each year we hold an advisory board with key industry leaders in pharma to help us develop the programme and identify the critcal issues for discussion.
Attendees to this year's advisory board included:
Chair: Iain Scott, Senior Editor, Industry and Management Research, Economist Intelligence Unit
Virginia Acha, Associate Director, Policy Development, Pfizer
Jane Griffiths, Head of Market Access, Janssen-Cilag EMEA
Glen Hodgson, Growth Director, Baxter Healthcare
Alex White, Vice-president, Europe, Emerging Markets, Asia-Pacific and Japan, GlaxoSmithKline
Frank Kumli, Lead Analyst Life Sciences, Ernst & Young
David Moran, Chief Executive Officer, Masters Pharmaceuticals
Richard Cassidy, Senior Director, Corporate Strategy and Planning, Astellas Pharma Europe
Stevo Knezevic, Head of Research and Development, Proximagen Group
Companies already confirmed to attend this year include:
Dealing with complex issues of fraud, regulatory compliance and business disputes can detract from efforts to achieve your company’s potential. At Ernst & Young we have over 1,200 fraud investigation and dispute professionals to help you better manage your fraud risk and compliance exposure. We assemble the right multidisciplinary and culturally aligned team to work with you and your legal advisors. We give the benefit of our broad sector experience, deep subject matter knowledge and the latest insights from our work worldwide.
For further information visit www.ey.com
Freshfields is a leading international law firm, providing legal advice to clients throughout the world. With over 2,500 lawyers in 27 key business centres, the firm provides a comprehensive service to national and multinational corporations, financial institutions and government.
For further information visit www.freshfields.com
PharmaTimes Magazine was launched in 1988. The PharmaTimes portfolio includes the well-respected monthly industry Magazine; three news elert services including World, UK and Clinical news; business forums, where thought-leaders meet to discuss the issues of the day; and a unique series of awards that recognise, reward and celebrate excellence.
Scripintelligence.com is the leading news, data and analysis service for the pharmaceutical and biotech industry. Scrip’s global coverage of business, R&D, policy & regulation, generics, drug development and clinical trials trends saves you valuable time and research costs.
Visit www.scripintelligence.com/freetrial today and register for free trial access.
Thomson Reuters can provide the knowledge, tools and expertise to help support your drug discovery and development activities, optimize your IP portfolio, identify licensing and partnering opportunities, deliver successful regulatory submissions, keep you in touch with the rapidly-changing pharmaceutical and chemical markets, and make informed, early decisions.
Supporting PR Agency:
M:Communications is Europe’s fastest growing and most sought after cross-border communications agency. M:’s highly experienced international healthcare team has a deep knowledge, passion and understanding of the sector and a proven track record in offering a fully integrated service to clients across all sub-sectors of healthcare.
Please note you will be directed to an external site to complete your booking.
2. BY POST OR FAX
Please download the registration form and return by:
3. BY PHONE
Please call customer services on +44 (0)207 576 8118